Market Newsdesk

SUFFOLK, Va., Aug. 25, 2021 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) announced today that its Board of Directors on August 25, 2021 declared its third-quarter shareholder cash dividend of $0.20 per common share payable on October 12, 2021 to shareholders of record on September 30, 2021.

The amount and declaration of future cash dividends are subject to Board of Directors’ approval in addition to regulatory restrictions.

About TowneBank:

Founded in 1999, TowneBank is a company built on relationships, offering a full range of banking and other financial services, with a mission of serving others and enriching lives. Dedicated to a culture of caring, Towne values all employees and members by embracing their diverse talents, perspectives, and experiences.

Today, the bank operates over 40 banking offices throughout Hampton Roads and Central Virginia, as well as Northeastern and Central North Carolina – serving as a local leader in promoting the social, cultural, and economic growth in each community. Towne offers a competitive array of business and personal banking solutions, delivered with only the highest ethical standards. Experienced local bankers providing a higher level of expertise and personal attention with local decision-making are key to the TowneBank strategy. Towne has grown its capabilities beyond banking to provide expertise through its controlled divisions and subsidiaries that include Towne Investment Group, Towne Wealth Management, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices Towne Realty, Towne 1031 Exchange, LLC, and Towne Vacations. With total assets of $15.80 billion as of June 30, 2021, TowneBank is one of the largest banks headquartered in Virginia.

Media contact:

G. Robert Aston, Jr., Executive Chairman, 757-638-6780
J. Morgan Davis, Chief Executive Officer, 757-673-1673

Investor contact:

William B. Littreal, Chief Financial Officer, 757-638-6813

• New Phase 3 data show booster (third) dose of COMIRNATY induces significant SARS-CoV-2 neutralizing antibody titers and demonstrated
  a favorable safety and tolerability profile
• SARS-CoV-2 neutralizing titers against the wild-type strain one month after booster dose were 3.3 times the titers one month after the second dose
• Pfizer and BioNTech intend to file these data with the European Medicines Agency (EMA) and other regulatory authorities around the world in coming weeks

NEW YORK, USA and MAINZ, GERMANY, August 25, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of a booster (third) dose of COMIRNATY^® (COVID-19 vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. The companies intend to complete submission of the sBLA by the end of this week.

The sBLA includes data from a Phase 3 clinical trial of 306 participants 18-55 years of age who received a booster (third) dose of COMIRNATY, between 4.8 and 8 months after completing the two-dose primary regimen, with a median follow-up time of 2.6 months post booster. The booster (third) dose of COMIRNATY elicited robust neutralizing antibodies to the wild-type strain in participants who were without evidence of SARS-CoV-2 infection through one month post dose three. SARS-CoV-2 50% neutralizing titers (PRNT50) after the third dose were 3.3 times the titers after the second dose. The post dose three neutralizing titers met the prespecified 1.5-fold non-inferiority criterion for success and were statistically superior. Moreover, 99.5% of participants had a four-fold response after the third dose, compared to 98.0% after the second dose. The titers after dose three met the pre-specified 10% non-inferiority margin for the difference in the four-fold seroresponse rates.

The reactogenicity profile within seven days after the booster (third) dose was typically mild to moderate. The most common events included injection site pain, fatigue, headache, muscle and joint pain, and chills. The frequency of any severe systemic event after the booster dose was low. The frequency of reactogenicity was similar to or better than after dose two of the primary series. The adverse event profile was generally consistent with other clinical data for COMIRNATY.

Pfizer and BioNTech intend to submit these data to a peer reviewed journal, as well as file these data with the European Medicines Agency (EMA) and other regulatory authorities around the world in the coming weeks.

A third dose of the Pfizer-BioNTech vaccine is not currently authorized for broad use in the U.S. However, under the current amended Emergency Use Authorization, a third dose was authorized on August 12 for administration to individuals at least 12 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union and the United Kingdom, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer), Canada and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.

Indication & Authorized Use

COMIRNATY^® (COVID-19 vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.

• It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older
• It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:
  • prevent COVID-19 in individuals 12 through 15 years, and
  • provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

The Pfizer-BioNTech COVID-19 vaccine has received EUA from FDA to:

• prevent COVID-19 in individuals 12 years of age and older, and
• provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

The FDA-approved COMIRNATY^® (COVID-19 vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY^® (COVID-19 vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.

EUA Statement

This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Important Safety Information  

Individuals should not get the Pfizer-BioNTech COVID-19 vaccine if they: 

• had a severe allergic reaction after a previous dose of this vaccine 
• had a severe allergic reaction to any ingredient of this vaccine  

Individuals should tell the vaccination provider about all of their medical conditions, including if they: 

• have any allergies 
• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) 
• have a fever 
• have a bleeding disorder or are on a blood thinner 
• are immunocompromised or are on a medicine that affects the immune system 
• are pregnant, plan to become pregnant, or are breastfeeding 
• have received another COVID-19 vaccine 
• have ever fainted in association with an injection 

The vaccine may not protect everyone. 

Side effects reported with the vaccine include: 

• There is a remote chance that the vaccine could cause a severe allergic reaction 
  • A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination 
  • Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness 
  • If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital 
• Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:  
  • chest pain 
  • shortness of breath 
  • feelings of having a fast-beating, fluttering, or pounding heart 
• Side effects that have been reported with the vaccine include: 
  • severe allergic reactions; non-severe allergic reactions such as rash, itching, hives, or swelling of the face; myocarditis (inflammation of the heart muscle); pericarditis (inflammation of the lining outside the heart); injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain 
• These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away 

There is no information on the use of the vaccine with other vaccines. 

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1‐800‐822‐7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985. 
Please click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of August 25, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and the rolling submission of a sBLA for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study;  the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when the submission of the sBLA for a potential booster (third) dose in the U.S. will be completed and accepted for review, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Forward-looking Statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including the definite approval of the BLA for BNT162b2 to prevent COVID-19 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of BNT162b2 in individuals 16 years of age and older and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence, a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.
For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Pfizer Contacts:

Media Relations
Amy Rose
+1 (212) 733-7410
[email protected]

Investor Relations
Christopher Stevo
+1 (212) 733-0437
[email protected]

BioNTech Contacts:

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
[email protected] 

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
[email protected]

SECAUCUS, N.J. and WARWICK, R.I., Aug. 25, 2021 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty apparel retailer in North America, and Plan International USA, a children’s rights and girls’ equality organization, announce a new partnership to establish an early childhood development (ECD) center at the Hawassa Industrial Park in Ethiopia, the largest industrial park in Africa. This partnership is designed to advance gender equity in the apparel industry and to provide safe, dependable child care.

With women making up the vast majority of Hawassa Industrial Park’s workforce, there is a pressing need for quality child care services. Lack of child care options makes it difficult, sometimes impossible, for women to fully participate in the workforce. The Children’s Place and Plan International USA believe that in order to help achieve gender diversity and equity in the workplace, improved access to child care is essential.

As a large importer of apparel from Ethiopia, The Children’s Place works with many suppliers and vendors based in Hawassa, and its funding of the Early Childhood Development center is an investment in helping to promote worker well-being in the region. Plan International has operated in Ethiopia since 1995 and brings years of experience in education, having established 51 ECD centers in the country. This project builds on Plan’s strategic efforts around worker wellness and gender equity at the Hawassa Industrial Park since 2019. The funding provided by The Children’s Place will be used to provide the Hawassa Industrial Park workforce with much needed child care services. The project will kick off in August 2021, with the goal of reaching over 1,000 children and adults when the center is operating at full capacity. At its core, the center is designed to provide a safe space for children, ages 0-6, of employees at the Hawassa Industrial Park to learn and grow in an inclusive and holistic way.

In addition to providing an essential service, the center will create job and skill development opportunities. The center will recruit staff from surrounding communities who will participate in a training program led by Plan International Ethiopia and receive certification in ECD. The center will also work to ensure workers’ needs are prioritized — for example, by offering staggered hours for early, mid-day or evening shifts. The center will not only work to provide a safe space for children to learn and grow, it will also help to remove barriers for the largely female workforce, increasing gender equality, improving access to higher paying jobs and enabling more women to achieve economic independence.  The Children’s Place and Plan International USA are also excited about what this shared-value partnership can do to help prepare children for success later in life in a formal school setting.

Jane Elfers, President and Chief Executive Officer of The Children’s Place, said, “This early childhood development center initiative will help to improve the lives and well-being of apparel factory workers and their children. We are honored to be part of something that can have such a profound impact on women and children.” Ms. Elfers continued, “We know that access to safe, dependable child care and early education opportunities are critical to transforming the lives of children and contribute to gender equality and economic independence for women. We are proud to partner with Plan International in this first of its kind early childhood development center in the Hawassa Industrial Park.”

Shanna Marzilli, Chief Marketing Officer of Plan International USA, said, “We are thrilled to bring The Children’s Place on board as our latest partner in support of girls rights and gender equality. Our partnership holds great promise for breaking down barriers for women, who represent the majority of the global apparel industry, and their children, to achieve their full potential. Through this investment in early childhood development and care, we hope to inspire other businesses to think strategically about how best to support worker wellbeing and gender equality around the world.”

About The Children’s Place

The Children’s Place is the largest pure-play children’s specialty apparel retailer in North America. The company designs, contracts to manufacture, sells at retail and wholesale, and licenses to sell fashionable, high-quality merchandise predominantly at value prices, primarily under the proprietary “The Children’s Place,” “Place,” “Baby Place” and “Gymboree” brand names. As of July 31, 2021, the Company had 708 stores in the United States, Canada and Puerto Rico, online stores at www.childrensplace.com and www.gymboree.com, and the company’s eight international franchise partners had 208 international points of distribution in 17 countries.

Contact: Investor Relations at 201-558-2400 extension 14500

 About Plan International USA

Powered by supporters, Plan International USA partners with adolescent girls, young women and children around the world to overcome oppression and gender inequality, providing the support and resources that are unique to their needs and the needs of their communities, ensuring they achieve their full potential with dignity, opportunity and safety. Founded in 1937, Plan International is an independent development and humanitarian organization that is active in more than 80 countries. For more information, visit https://planusa.org.

Contact: Brit Rocourt, Vice President of Philanthropy and Partnerships at [email protected]

SAN MATEO, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) — Momentive (NASDAQ: MNTV—formerly SurveyMonkey), a leader in agile experience management, today announced that Casey’s General Stores, Inc., a Midwest-based chain of 2,300 convenience stores, is using Momentive to fuel its customer and employee experience management and market research efforts. With Momentive and SurveyMonkey Enterprise, Casey’s uses data to measure employee experience, track product awareness and advertising effectiveness, and launch new products.

When Casey’s formed their Guest Insights team to better understand customers and collect data to inform business decisions, Casey’s selected SurveyMonkey Enterprise to quickly deploy internal and external surveys to measure employee feedback, product awareness, and consumer behavior. After seeing success with SurveyMonkey Enterprise, Casey’s expanded their research footprint with Momentive’s brand and market insights solutions to track brand awareness and sentiment, and to better understand the impact of advertising campaigns.

Casey’s recently used Momentive to test different types of bacon in its breakfast sandwiches, discovering a clear customer preference (and the fact that many customers were unaware the chain even offered sandwiches). This prompted Casey’s to not only reformulate their breakfast sandwiches, but also update their marketing to increase awareness of their sandwich offerings. Casey’s also used Momentive to test different coffee machine designs, using the feedback to update the coffee machines in every store.

About SurveyMonkey Enterprise

SurveyMonkey Enterprise by Momentive is a leading AI-powered feedback management platform that’s built to seamlessly integrate with business systems like Salesforce, Tableau, Marketo, Eloqua, ServiceNow, Zendesk, Microsoft Teams, and Microsoft Power BI. It is intuitive to use and delivers speed to insights so businesses can realize ROI in days, not months. With over 20 years of experience built into the platform, users can quickly turn feedback into rich insights to confidently drive meaningful change in the experiences they deliver. Companies like Adobe, Verizon, Johnson & Johnson, and Allbirds rely on the solution to drive transformational outcomes across their business. Learn more at surveymonkey.com/mp/enterprise.

About Momentive

Momentive (NASDAQ: MNTV—formerly SurveyMonkey) is a leader in agile experience management, delivering powerful, purpose-built solutions that bring together the best parts of humanity and technology to redefine AI. Momentive products, including GetFeedback, SurveyMonkey, and Momentive brand and market insights solutions, empower ​decision-makers at 345,000 organizations worldwide to shape exceptional experiences. More than 20 million active users rely on Momentive to fuel market insights, brand insights, employee experience, customer experience, and product experience. Ultimately, the company’s vision is to raise the bar for human experiences by amplifying individual voices. Learn more at momentive.ai.